hat
Kòm nan mwa Out 2016 perampanel yo te etidye ak devlopman sispann nan migrèn, paralezi aparèy nè, dwòg neropatik, ak maladi Parkinson la
eng
As of August 2016 perampanel had been studied and development discontinued in migraine, multiple sclerosis, neuropathic pain, and Parkinson's disease